&lt;h2&gt;&lt;span style=&quot;color: #ff99cc;&quot;&gt;&lt;strong&gt;OVERVIEW&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;
&lt;p&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;The Gastrointestinal Dysmotility test is employed to evaluate and diagnose conditions associated with abnormal movement or functionality of the gastrointestinal tract. This includes disorders such as gastroparesis, characterized by delayed stomach emptying, and intestinal pseudo-obstruction, which involves diminished or absent intestinal movement, as well as other motility disorders impacting the digestive system. By measuring critical factors such as transit times, muscle contractions, and the coordination of movements, the test provides valuable insights into the gastrointestinal tract&#39;s functioning. This information is essential for accurately diagnosing and managing gastrointestinal dysmotility disorders, ultimately improving patient outcomes.&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;hr /&gt;
&lt;h2&gt;&amp;nbsp;&lt;/h2&gt;
&lt;h3&gt;&lt;span style=&quot;color: #ff99cc;&quot;&gt;&lt;strong&gt;WHAT IS IT USED FOR?&lt;/strong&gt;&lt;/span&gt;&lt;/h3&gt;
&lt;ul&gt;
&lt;li&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Examining unexpected weight loss, early feeling of fullness, loss of appetite, feelings of sickness, throwing up, difficulty passing stool, or experiencing diarrhea in a patient with a prior or familial history of cancer or autoimmune conditions.&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Conducting a targeted investigation for cancer.&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Exploring digestive symptoms arising during or following cancer treatment, not attributable to recurring cancer, spreading of cancer, or treatment side effects; identifying autoantibodies in this context assists in distinguishing autoimmune gastrointestinal issues from chemotherapy-related effects.&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Identifying initial signs of cancer recurrence in previously positive patients whose levels of one or more autoantibodies are increasing.&lt;/span&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;h2&gt;&amp;nbsp;&lt;/h2&gt;
&lt;h3&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;color: #ff99cc;&quot;&gt;METHOD NAME&lt;/span&gt;&lt;br /&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h3&gt;
&lt;ul&gt;
&lt;li&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;ANN1S, AN1TS, APBIS, APBTS, DPPIS, DPPTS, CRMS, CRMTS, PCAB2, PC2TS: Indirect Immunofluorescence Assay (IFA)&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;APBCS, CS2CS, LG1CS, DPPCS: Cell Binding Assay (CBA)&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;CRMWS: Western Blot (WB)&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;AN1BS, AN2BS: Immunoblot (IB)&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;GANG: Radioimmunoassay (RIA)&lt;/span&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;h2&gt;&amp;nbsp;&lt;/h2&gt;
&lt;h3&gt;&lt;span style=&quot;color: #ff99cc;&quot;&gt;&lt;strong&gt;AVAILABILITY&lt;/strong&gt;&lt;/span&gt;&lt;/h3&gt;
&lt;p&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;TBC&lt;/span&gt;&lt;/p&gt;
&lt;h2&gt;&amp;nbsp;&lt;/h2&gt;
&lt;h3&gt;&lt;span style=&quot;color: #ff99cc;&quot;&gt;&lt;strong&gt;REPORTING NAME&lt;/strong&gt;&lt;/span&gt;&lt;/h3&gt;
&lt;p&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;GI Dysmotility, Autoimm/Paraneo, S&lt;/span&gt;&lt;/p&gt;
&lt;h2&gt;&amp;nbsp;&lt;/h2&gt;
&lt;h3&gt;&lt;span style=&quot;color: #ff99cc;&quot;&gt;&lt;strong&gt;OTHER NAME&lt;/strong&gt;&lt;/span&gt;&lt;/h3&gt;
&lt;ul&gt;
&lt;li&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;ANNA (Antineuronal Nuclear Antibody)&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Anti-CV2&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Anti-Enteric Neuronal Antibody&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Anti-Hu&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Antineuronal&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Cerebellar Antibodies&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Chorea&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Collapsin Response-Mediator Protein-5 Antibody (CRMP-5), Serum&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Cramp-Fasciculation&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;CRMP-5, IgG&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;DPPX&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Dorsal Root Ganglion Antibody&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Hu Antibody&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Isaacs Disease&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Motor End-Plate Antibody&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Myoid Antibody&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Neuromuscular Hyperexcitability&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Neuromyotonia&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Neuronal Ganglionic Acetylcholine Receptor Antibody&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Neuronal Nuclear Antibody Panel&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Neuronal-Anti&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Paraneoplastic Antibodies&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Paraneoplastic Autoantibody Evaluation&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Paraneoplastic Neurological Autoimmunity&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Dipeptidyl aminopeptidase-like protein 6&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;AP3B2&lt;/span&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;h2&gt;&amp;nbsp;&lt;/h2&gt;
&lt;h3 id=&quot;SpecimenType-title&quot;&gt;&lt;span style=&quot;color: #ff99cc;&quot;&gt;&lt;strong&gt;SPECIMEN TYPE&lt;/strong&gt;&amp;nbsp;&lt;/span&gt;&lt;/h3&gt;
&lt;p&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Serum&lt;/span&gt;&lt;/p&gt;
&lt;h2&gt;&amp;nbsp;&lt;/h2&gt;
&lt;h3&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;color: #ff99cc;&quot;&gt;SHIPPING INSTRUCTIONS&lt;/span&gt;&lt;br /&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h3&gt;
&lt;p&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;TBC&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;h3&gt;&lt;strong style=&quot;color: #ff99cc;&quot;&gt;SPECIMEN REQUIRED&lt;/strong&gt;&lt;/h3&gt;
&lt;p style=&quot;font-weight: 400;&quot;&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;&lt;strong&gt;Collection Container/Tube:&lt;/strong&gt;&amp;nbsp;Red top&lt;/span&gt;&lt;/p&gt;
&lt;p style=&quot;font-weight: 400;&quot;&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;&lt;strong&gt;Specimen Volume:&lt;/strong&gt; 4 mL&lt;/span&gt;&lt;/p&gt;
&lt;p style=&quot;font-weight: 400;&quot;&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;&lt;strong&gt;Collection Instructions:&lt;/strong&gt;&amp;nbsp;Spin and portion out serum into a plastic container.&lt;/span&gt;&lt;/p&gt;

What to Do When Condom Broke? - Students Get Emergency PEP at Special Price at PULSE Clinic

Get TELDY (TLD) in Hong Kong - Generic Antiretroviral for HIV Treatment

Gastrointestinal Dysmotility, Autoimmune/Paraneoplastic Evaluation, Serum